Veracyte, Inc.

Day range

$47.70 – $48.96

Open

$48.24

Prev close

$47.93

Volume

748.1K

Market cap

$3.85B

Shares out

80.39M

P/E

33.66

P/S

6.86

P/B

2.78

P/FCF

23.21

ROE

8.3%

ROA

7.7%

Debt/Equity

0.00

Div yield

0.00%

As of Oct 23, 2026

• Merger agreementSep 14, 2026

  On September 10, 2026, Veracyte, Inc. entered into an Agreement and Plan of Merger with Compass Merger Sub, Inc., Convergent Genomics Inc., and Shareholder Representative Services LLC. Pursuant to the terms of the Merger Agreement, Veracyte agreed to acquire Convergent through the merger of Merger Sub with and into Convergent.

• Annual meeting resultsJun 11, 2026

  The stockholders of the Company voted on the following proposals at the Annual Meeting. The results of such votes are as follows: 1. The following directors were nominated to serve until the 2027 annual meeting of stockholders... Each of the nine nominees for director was elected to serve until the 2027 annual meeting of stockholders and until their successors are duly elected and qualified.

• Executive officer appointmentMar 16, 2026

  On March 16, 2026, Veracyte, Inc. (the "Company") announced the appointment of Dr. Kevin Haas, 40, as its Chief Development and Technology Officer, effective March 24, 2026. Prior to joining the Company, Dr. Haas served as Chief Technology Officer of Myriad Genetics, Inc.

• Guidance issuance or updateJan 12, 2026

  Veracyte expects to report adjusted EBITDA margin of greater than 25% for the full year ended December 31, 2025. Veracyte is unable to provide an estimate of net income margin, the most closely comparable GAAP measure to adjusted EBITDA margin, for the full year ended December 31, 2025 or related reconciliation tables without unreasonable effort.

• Annual meeting resultsJun 18, 2025

  The stockholders of the Company voted on the following proposals at the Annual Meeting. The results of such votes are as follows: 1. The following directors were nominated to serve until the 2026 annual meeting of stockholders... Each of the seven nominees for director was elected to serve until the 2026 annual meeting of stockholders and until their successors are duly elected and qualified.

• WSTWest Pharmaceutical Services, Inc.+0.66%
• GMEDGLOBUS MEDICAL INC+0.52%

Days to cover

5.9

Short interest

10.18M

Avg volume

1.73M

As of Sep 30, 2026 · reported to FINRA twice monthly.

• Phase III Trial Shows Veracyte’s Decipher Prostate Test Can Predict Benefit from Adding Abiraterone to Treatment in Very High-Risk Prostate Cancer
  positiveGlobeNewswire Inc.· Oct 23, 2026
• Will Veracyte (VCYT) Beat Estimates Again in Its Next Earnings Report?
  positiveZacks Investment Research· Oct 21, 2026
• How to Boost Your Portfolio with Top Medical Stocks Set to Beat Earnings
  positiveZacks Investment Research· Oct 21, 2026
• Veeva Systems' Basics Gains Traction With 175+ Emerging Biotech Firms
  positiveZacks Investment Research· Oct 13, 2026
• ANGO Q1 Earnings Beat Estimates on Med Tech Growth, Revenues Up Y/Y
  neutralZacks Investment Research· Oct 9, 2026